Form 4 for ABCL AbCellera Biologics Inc.
Accepted 2026-06-03 14:23:16 ET · period of report 2026-06-03 · accession 0001834411-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-03 14:23 | 2026-06-03 | ABCL | Booth Andrew | CFO | M - OptEx | $0.19 | +250.0K | 445.6K | +128% | +$47.5K |
| D | 2026-06-03 14:23 | 2026-06-03 | ABCL | Booth Andrew | CFO | M - OptEx | $0.00 | -250.0K | 8.50M | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-06-03 | M | A | 250,000 | $0.19 | 445,600 | D | — | — | |
| 2 | Derivative | Share option (right to buy) | 2026-06-03 | M | D | 250,000 | $0.00 | 8,501,849 | D | $0.19 · — to 2026-06-15 | 250,000 Common Shares | (F1) The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. |